Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Innospace's rocket crashes in first commercial launch in Brazil; shares tumble - 2The Response Uncovered: Disentangling the Secrets of the Universe
- 3US FDA grants market authorization to six on! PLUS nicotine pouch products
- 4Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- 5An Investigate of 6 Creative Specialty Mixed drinks
- 21 Incredibly Interesting Contemplations To Observe Consistently
- 10 Energizing Vocations in the Innovation Business
- Solid Propensities: Little Changes for a Superior Life
- Figure out How to Augment the Advantages of a Web-based Degree
- Obamacare enrollment declines as US subsidies expire
- The Most Rousing Ladies Business visionaries of Today
- Ukraine demands army of 800,000 under peace plan
- Boeing's troubled capsule won't carry astronauts on next space station flight
- The most effective method to Boost Eco-friendliness in Your Volvo XC40
